AllergoSan USA Sponsors Institute for Natural Medicine Residency Consortium
PORT CHESTER, NY August 16, 2021: AllergoSan USA, home of Omni-Biotic probiotic
brands, today announced their sponsorship of the Institute for Natural Medicine Residency
Consortium (IRC). In partnership with schools of naturopathic medicine and leading
naturopathic clinics in the United States, the IRC provides a much needed and sustainable
model for a more formal and uniform naturopathic residency experience. The IRC model
ensures extensive, post-graduate clinical experience, as well as advanced practical and small
business management training.
“We are honored to contribute to the success of this unique program to enhance the education
and business acumen of newly graduated students.” commented AllergoSan USA’s Chief
Operating Officer, Hannah Kleinfeld. “The INM residency will not only benefit individual
naturopathic physicians, but also the profession as a whole.”
The Institute for Natural Medicine (INM) CEO, Michelle Simon, PhD, ND is also enthusiastic
about the partnership. “I am thrilled to welcome AllergoSan USA (Omni-Biotic) to the INM
Residency Consortium sponsorship family. As a brand committed to the scientific process,
evidence based performance, and targeted probiotic formulations, Omni-Biotic is optimally
aligned with the profession of naturopathic medicine! Their support comes at a time when the
addition of naturopathic practitioners, trained in whole person medicine, has never been more
important to primary care. We are so grateful for AllergoSan USA’s recognition of the value and
potential of the IRC program.”
ABOUT INM
The Institute for Natural Medicine is a non-profit 501(c)(3) organization, partnered with the American
Association of Naturopathic Physicians. Their mission is to transform healthcare in America by increasing
both public awareness of naturopathic medicine and access to naturopathic doctors for patients.
ABOUT OMNI-BIOTIC
Omni-Biotic has been a leading professional probiotic brand in Europe for more than 25 years. In 2019,
targeted Omni-Biotic blends were introduced to the American market. Grounded in extensive research
and controlled clinical studies, Omni-Biotic is committed to evidence based product development and
synergistic formulation.
